Not provided
Not provided
Not provided
Not provided
Not provided
Insufficient funding
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
There is very limited data on the utilization of National Cancer Institute Comprehensive Cancer Center (NCI-CCC) satellite sites in general. Of what is available, most is in regards to providing chemotherapy at facilities closer to patients' home. These "satellite chemotherapy infusion centers", typically community-based treatment locations at community hospitals/facilities, freestanding clinics, or mobile units, are reported to be well liked by patients who utilize their services and reduce their travel times and expenses. In these studies patients still remained in the care of their current provider and site and are required to travel to the site for clinical visits and other appointments. It is currently unknown if patients are willing to transfer their care to a different provider to alleviate travel burden. In addition, although increased travel burden has been lower quality of life in cross-sectional studies, no data exists suggesting that these reducing travel burden can improve these outcomes intra-patient, to the knowledge of the investigators.
The patient roles of the multiple myeloma clinical providers at the Siteman primary location have grown in recent years. The providers have determined a need to refer some patients to the satellite sites to relieve congestion at the site while also hopefully improving the clinical experience for those patients. This study is a natural experiment of this process.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Care transition | Experimental | -At baseline, the participant and the provider will make a decision on if the participant will transfer care to a satellite location. |
|
| No care transition | Active Comparator | -At baseline, the participant and the provider will make a decision on if the participant will transfer care to a satellite location. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Care transition | Other | Cancer care is transitioned to a satellite site. |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of eligible participants who successfully transfer to the provider at a satellite location | At time of transfer decision (day 1) |
| Measure | Description | Time Frame |
|---|---|---|
| Types of candidacy that providers use for transfer of care to satellite sites | Qualitative data collection | At time of transfer decision (day 1) |
| Treatment burden of participants as measured by the Modified Treatment Burden Questionnaire |
Not provided
Eligibility Criteria
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Mark Fiala, Ph.D., MSW | Washington University School of Medicine | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Washington University School of Medicine | St Louis | Missouri | 63110 | United States |
Not provided
| Label | URL |
|---|---|
| Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009101 | Multiple Myeloma |
| D000086522 | Financial Stress |
| D017060 | Patient Satisfaction |
| ID | Term |
|---|---|
| D054219 | Neoplasms, Plasma Cell |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D020141 | Hemostatic Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D010360 | Patient Transfer |
| ID | Term |
|---|---|
| D003266 | Continuity of Patient Care |
| D005791 | Patient Care |
| D013812 | Therapeutics |
| D006760 | Hospitalization |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| No care transition |
| Other |
Cancer care is not transitioned to a satellite site. |
|
| Through completion of follow-up (estimated to be 6 months) |
| Satisfaction of with participant-provider interactions as measured by the Questionnaire on the Quality of Physician-Patient Interaction |
| Through completion of follow-up (estimated to be 6 months) |
| Financial toxicity of participants as measured by the Comprehensive Score for Financial Toxicity |
| Through completion of follow-up (estimated to be 6 months) |
| Participant rationales for opting to transfer to a satellite site or maintain care at their usual site. | A sample of 20 patients, approximately 10 who decided to transfer and 10 who declined, will be surveyed in regards to the reason(s) for their decision as part of a sub-study. Patients who were not enrolled in the prospective portion of the study, either due to declining or not approached, will be allowed to enroll in the sub-study as long as they were offered the ability to transfer to a satellite site by their provider. | Through completion of follow-up (estimated to be 6 months) |
| D014652 |
| Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D010265 | Paraproteinemias |
| D001796 | Blood Protein Disorders |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D006474 | Hemorrhagic Disorders |
| D008232 | Lymphoproliferative Disorders |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
| D013315 | Stress, Psychological |
| D001526 | Behavioral Symptoms |
| D001519 | Behavior |
| D000074822 | Treatment Adherence and Compliance |
| D015438 | Health Behavior |
| D006296 |
| Health Services |
| D005159 | Health Care Facilities Workforce and Services |
| D011320 | Primary Health Care |
| D003191 | Comprehensive Health Care |
| D010346 | Patient Care Management |
| D006298 | Health Services Administration |